Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2231 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2231 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

active not recruiting Phase III Gastroenterology
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
Maralixibat safely reduced severe itching in patients with cholestatic liver disease who hadn't responded to other treatments.
11 Aug 2026 NCT06553768
● Recruiting Phase III
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
New drug tested for Duchenne muscular dystrophy in patients whose genetic mutations can be treated by skipping exon 44.
11 Aug 2026 NCT07587242
● Recruiting Phase III Oncology
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Trial testing whether mRNA vaccine plus immunotherapy reduces lung cancer recurrence after surgery in high-risk patients.
10 Aug 2026 NCT07513376
● Recruiting Phase III Gastroenterology
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn’s Disease
Trial testing a new drug (Afimkibart) for treating moderate-to-severe Crohn's disease in children.
10 Aug 2026 NCT07298421
active not recruiting Phase III Diabetes / Metabolic
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Setmelanotide daily injections tested for weight loss and quality of life improvement in acquired hypothalamic obesity patients aged 4+ years.
10 Aug 2026 NCT05774756
● Recruiting Phase III Rheumatology
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Baricitinib safety and effectiveness for children aged 1-17 with juvenile idiopathic arthritis.
07 Aug 2026 NCT03773965
active not recruiting Phase III Infectious Disease
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn’s Disease
Risankizumab maintains remission in moderate-to-severe Crohn's disease; studies examine dosing schedules, long-term safety, and injection device preferences.
07 Aug 2026 NCT03105102
● Recruiting Phase III
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
INCA033989 is tested against standard treatment in patients with essential thrombocythemia and CALR mutations who've had previous cytoreductive therapy.
06 Aug 2026 NCT07623200
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Trial testing whether nerandomilast tablet improves symptoms and slows disease in systemic sclerosis patients over one to four years.
06 Aug 2026 NCT07497087
active not recruiting Phase III Diabetes / Metabolic
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Experimental weight-loss injection cagrilintide tested against placebo in overweight or obese adults over 18 months.
06 Aug 2026 NCT07220642
● Recruiting Phase III
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
NXT007 compared to standard Factor VIII treatment for preventing bleeding in people with moderate-to-severe hemophilia A.
06 Aug 2026 NCT07416526
● Recruiting Phase III Oncology
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
What is being tested: BGB-43395 (a novel protein degrader) combined with letrozole is being compared against standard CDK4/6 inhibitors plus letrozole as first-line treatment…
06 Aug 2026 NCT07492641
● Recruiting Phase III
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Trial testing whether adding elritercept to ruxolitinib improves anaemia and symptoms in myelofibrosis patients versus placebo.
05 Aug 2026 NCT07623161
active not recruiting Phase III
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Aficamten improves symptoms and exercise ability in non-obstructive hypertrophic cardiomyopathy compared to placebo.
05 Aug 2026 NCT06081894
● Recruiting Phase III Oncology
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
What is being tested: RLY-2608 (zovegalisib), a PI3K inhibitor, combined with fulvestrant is being compared against capivasertib (another PI3K inhibitor) plus fulvestrant in patients…
05 Aug 2026 NCT06982521
active not recruiting Phase III Diabetes / Metabolic
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Semaglutide injection tested against placebo over five years to see if it slows diabetic eye disease in type 2 diabetes.
04 Aug 2026 NCT03811561
● Recruiting Phase III Oncology
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Treatment being tested: Ifinatamab deruxtecan (I-DXd), a novel antibody-drug conjugate targeting DLR3, is being evaluated for efficacy and safety in patients with advanced or…
04 Aug 2026 NCT06644781
● Recruiting Phase III
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
Apraglutide versus placebo for short bowel syndrome: 24-week trial testing effectiveness and safety in 124 patients.
03 Aug 2026 NCT07742735
active not recruiting Phase III Diabetes / Metabolic
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Cagrilintide (new injection) versus placebo tested for weight loss in overweight people with type 2 diabetes over 18 months.
03 Aug 2026 NCT07220759
● Recruiting Phase III Oncology
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Treatment being tested: Combination therapy of belzutifan (a HIF-2α inhibitor) and zanzalintinib (a VEGFR/TKI) in patients with recurrent advanced renal cell carcinoma following prior…
03 Aug 2026 NCT07227402
● Recruiting Phase III
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Upadacitinib tablets tested for safety and effectiveness in treating severe hair loss caused by immune system attack in adolescents and adults.
31 Jul 2026 NCT06012240
● Recruiting Phase III Rheumatology
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Trial comparing risankizumab versus adalimumab injections for childhood psoriatic arthritis, measuring safety and disease improvement over 124 weeks.
31 Jul 2026 NCT06100744
active not recruiting Phase III
Nipocalimab in Moderate to Severe Sjogren’s Disease
Nipocalimab injection appears safe and effective for treating moderate to severe Sjögren's disease symptoms.
31 Jul 2026 NCT06741969
● Recruiting Phase III Rheumatology
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Nipocalimab reduced disease activity better than placebo in moderate-to-severe lupus patients.
31 Jul 2026 NCT07438496
active not recruiting Phase III Oncology
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Nivolumab versus placebo to prevent cancer recurrence in patients with liver cancer after surgery or ablation.
31 Jul 2026 NCT03383458
● Recruiting Phase III Oncology
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
What is being tested: TAR-210 (a novel therapeutic agent) is being compared against standard intravesical chemotherapy in BCG-treated patients with high-risk non-muscle-invasive bladder cancer…
31 Jul 2026 NCT06919965
active not recruiting Phase III Infectious Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
Two-drug long-acting injections (cabotegravir and rilpivirine) monthly maintain HIV suppression as well as daily tablets in treatment-experienced patients.
30 Jul 2026 NCT02938520
active not recruiting Phase III Oncology
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
New antibody-drug conjugate T-DXd, with or without pertuzumab, compared to standard chemotherapy for HER2-positive advanced breast cancer.
30 Jul 2026 NCT04784715
active not recruiting Phase III
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
Trial testing whether leriglitazone drug slows cerebral adrenoleukodystrophy progression in adult men.
29 Jul 2026 NCT05819866
active not recruiting Phase III Oncology
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Pembrolizumab plus chemotherapy before surgery, then pembrolizumab alone after surgery, improves survival in resectable lung cancer.
29 Jul 2026 NCT03425643
active not recruiting Phase III Oncology
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Olaparib vs placebo as maintenance therapy after chemotherapy in BRCA-mutated ovarian cancer patients.
29 Jul 2026 NCT01874353
active not recruiting Phase III Oncology
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Sacituzumab govitecan improves survival compared to standard treatment in advanced endometrial cancer patients previously treated with chemotherapy and immunotherapy.
29 Jul 2026 NCT06486441
● Recruiting Phase III Respiratory / COPD / Asthma
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
What is being tested: Long-term safety, tolerability, and efficacy of seralutinib, an orally inhaled therapeutic agent, in patients with pulmonary arterial hypertension (PAH) who…
29 Jul 2026 NCT06274801
active not recruiting Phase III Oncology
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
New drug volrustomig plus chemotherapy compared with pembrolizumab plus chemotherapy for advanced lung cancer with low PD-L1 levels.
28 Jul 2026 NCT05984277
active not recruiting Phase III Oncology
Phase III Study of AK112 for NSCLC Patients
AK112 plus chemotherapy improved outcomes in advanced lung cancer patients whose tumours had stopped responding to targeted therapy.
28 Jul 2026 NCT06396065
● Recruiting Phase III Respiratory / COPD / Asthma
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
What is being tested: Depemokimab, a novel therapeutic agent, is being evaluated as an add-on treatment for moderate to severe COPD patients with Type…
28 Jul 2026 NCT07177339
● Recruiting Phase III Oncology
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Treatment being tested: A combination of two targeted therapies—avutometinib (a MEK inhibitor) and defactinib (a FAK inhibitor)—compared against standard investigator-selected treatments in patients with…
28 Jul 2026 NCT06072781
● Recruiting Phase III
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
This trial tests whether intravenous AOC 1020 safely and effectively treats facioscapulohumeral muscular dystrophy compared to placebo.
27 Jul 2026 NCT07038200
active not recruiting Phase III Oncology
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Pembrolizumab before and after surgery with radiotherapy improves survival in advanced head and neck cancer compared to radiotherapy alone.
27 Jul 2026 NCT03765918
active not recruiting Phase III Rheumatology
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
Subcutaneous anifrolumab (an interferon-blocking drug) improved outcomes in moderate-to-severe lupus patients already on standard treatment.
27 Jul 2026 NCT04877691
● Recruiting Phase III Oncology
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
What is being tested: A phase 3 randomized trial comparing two experimental combination regimens (N-803 plus tislelizumab with docetaxel, or prior failed PD-1/PD-L1 checkpoint…
27 Jul 2026 NCT06745908
active not recruiting Phase III
A Study of Acalabrutinib vs Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acalabrutinib compared to chemotherapy plus antibody therapy for previously treated blood cancer patients.
24 Jul 2026 NCT02970318
● Recruiting Phase III Rheumatology
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Apremilast was tested against placebo in children aged 5-17 with juvenile psoriatic arthritis to assess its effectiveness.
24 Jul 2026 NCT04804553
active not recruiting Phase III
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Long-term safety study of secukinumab (an IL-17 inhibitor) in patients with polymyalgia rheumatica to assess tolerability and adverse effects.
24 Jul 2026 NCT06331312
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
Trial testing nerandomilast tolerance and effectiveness in children aged 2-17 with interstitial lung disease over 2.5-5 years.
24 Jul 2026 NCT07366034
● Recruiting Phase III Cardiology / Cardiovascular
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet’s Disease
Intervention tested: Apremilast (a phosphodiesterase-4 inhibitor) versus placebo for treating oral ulcers in children with Behçet's disease, addressing a significant unmet need in pediatric…
24 Jul 2026 NCT04528082
● Recruiting Phase III Cardiology / Cardiovascular
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Treatment tested: Inclisiran, a PCSK9 inhibitor administered via subcutaneous injection, being evaluated for its ability to lower LDL cholesterol in paediatric patients with homozygous…
24 Jul 2026 NCT06597006
● Recruiting Phase III Oncology
Vorasidenib Maintenance for IDH Mutant Astrocytoma
What is being tested: Vorasidenib (an IDH inhibitor) as maintenance therapy post-chemoradiotherapy versus placebo in IDH-mutant astrocytoma, with progression-free survival as the primary endpoint.…
24 Jul 2026 NCT06809322
active not recruiting Phase III Oncology
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Trial comparing new cancer-targeting drug sigvotatug vedotin versus standard docetaxel chemotherapy in previously treated advanced lung cancer patients.
23 Jul 2026 NCT06012435
active not recruiting Phase II / Phase III
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
Zanubrutinib reduced protein in urine in primary membranous nephropathy patients and was compared against standard tacrolimus treatment.
23 Jul 2026 NCT05707377